<DOC>
	<DOCNO>NCT02460978</DOCNO>
	<brief_summary>The purpose study determine add dapagliflozin insulin safe effective therapy improve glycemic control patient type 1 diabetes .</brief_summary>
	<brief_title>Dapagliflozin Evaluation Patients With Inadequately Controlled Type 1 Diabetes</brief_title>
	<detailed_description>Study Classification : Safety , Efficacy Pharmacokinetics/dynamics</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Diagnosis Type 1 Diabetes mellitus ( T1DM ) Central laboratory Cpeptide &lt; 0.7 ng/ml ( 0.23 nmol/L ) Insulin use least 12 month per patient report medical record Method insulin administration ( MDI CSII ) must unchanged least 3 month prior screen Subjects must total insulin dose ≥ 0.3 U/kg/day least 3 month prior screen If MDI insulin administration , subject must ≥ 3x injection per day Screening Visit : Central laboratory HbA1c ≥ 7.7 % ≤ 11.0 % Body mass index ( BMI ) ≥ 18.5 kg/m2 History Type 2 Diabetes mellitus ( T2DM ) maturity onset diabetes young ( MODY ) , pancreatic surgery , chronic pancreatitis could result decreased beta cell capacity Taking noninsulin antihyperglicemic agent within 1 month prior screen Taking GLP1 receptor agonist within 2 month prior screen weekly administration within 1 month prior screen twice daily administration Taking metformin and/or thiazolidinediones within 2 month prior screen History diabetes ketoacidosis require medical intervention within 1 month prior screen History hospital admission glycemic control ( either hyperglycemia hypoglycemia ) within 1 month prior screen Frequent episode severe hypoglycemia ( one episode require medical assistance , emergency care ) , and/or glucagon therapy administer thirdparty individual within 1 month prior screen History Addison 's disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Dapagliflozin</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>Add insulin</keyword>
	<keyword>Oral Antidiabetic</keyword>
	<keyword>Type 1 diabetes</keyword>
</DOC>